Urinary Bladder Cancer

Effectiveness and Safety of First-Line Atezolizumab in Locally Advanced or Metastatic Urothelial Cancer: The IMFLAME Study

The purpose of this analysis is to evaluate the real-word effectiveness and safety of atezolizumab monotherapy as first line treatment in locally advanced or mUC ineligible for platinum-based chemotherapies.

Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)

This poster reports a post hoc analysis of clinical outcomes with atezolizumab in previously treated patients with metastatic urinary tract carcinoma based on response to prior chemotherapy and type of platinum agent, using data from the single-arm prospective SAUL study. Outcomes reported in this subgroup analysis include assesses efficacy, overall survival, overall response rate, and duration of response.

Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT RT): An open label, single arm, multicenter, phase II

This poster presents an open-label, single-arm multicenter Phase II trial evaluating atezolizumab combined with radiation therapy as bladder preservation therapy in patients with invasive bladder cancer. The poster presents data from an interim analysis on efficacy and safety.

Independent content

What is the optimal perioperative chemotherapy regimen for muscle-invasive bladder cancer?

Srikala Sridhar gives her thoughts on the VESPER V05 trial comparing dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with gemcitabine plus cisplatin as perioperative treatment in people with muscle-invasive bladder cancer.

Independent content

Cetrelimab boosts erdafitinib response in advanced urothelial carcinoma

Srikala Sridhar comments on the interim analysis of the NORSE study of first-line erdafitinib plus cetrelimab in cisplatin-ineligible patients with advanced urothelial carcinoma and fibroblast growth factor receptor alterations.

Independent content

ESMO 2021 Genitourinary cancer highlights

Delegates seeking the latest in genitourinary cancer research have been treated to a range of key trial findings in the first days of the ESMO Congress 2021.

External site

Urinary Bladder Cancer

Ask a question or share feedback